For the quarter ending 2026-03-31, MED had -$17,774K decrease in cash & cash equivalents over the period. -$836K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 76,044 | 75,096 | 89,409 | - |
| Cost of sales | 24,288 | 22,956 | 27,250 | - |
| Selling, marketing, and after sales support | 34,681 | 36,103 | 41,543 | - |
| Distribution | 3,452 | 4,121 | 3,815 | - |
| Technology | 9,311 | 11,013 | 11,123 | - |
| Administrative and corporate support functions | 5,711 | 6,534 | 9,063 | - |
| Equity compensation | 1,896 | 2,172 | 696 | - |
| Other income | 1,354 | 1,421 | 1,423 | - |
| Provision for income taxes | 181 | 11,737 | -397 | - |
| Net loss | -2,122 | -18,119 | -2,261 | 1,708 |
| Depreciation and amortization | 3,483 | 3,465 | 3,452 | 7,325 |
| Non-cash lease expense | 1,160 | 1,165 | 1,160 | 2,299 |
| Share-based compensation | 1,896 | 2,172 | 910 | 4,557 |
| Gain on sale of assets held for sale | 2,184 | - | - | - |
| Loss on sale or disposal of property, plant and equipment | -63 | -372 | -606 | -395 |
| Realized gain on sale of investment securities | 25 | 7 | 0 | 3,303 |
| Amortization of discount on investment securities | 164 | 156 | 515 | 0 |
| Deferred income taxes | 0 | 12,108 | -648 | 0 |
| Unrealized loss (gain) on equity investment securities | -66 | 3 | 14 | 0 |
| Non-cash charges for supply chain optimization | - | 0 | 358 | -358 |
| Inventories | 1,175 | -2,977 | -6,996 | -12,220 |
| Prepaid expenses and other current assets | -649 | 2,245 | -2,233 | -585 |
| Other assets | -262 | 1,888 | -139 | 308 |
| Accounts payable and accrued expenses | -1,449 | -4,303 | -516 | -19,094 |
| Income taxes | -200 | -816 | 213 | -5,998 |
| Net cash flow provided by operating activities | 260 | -5,278 | 12,113 | 28 |
| Purchase of investment securities | 49,320 | 32,912 | 20,433 | 31,062 |
| Proceeds from sale and maturities of investment securities | 29,646 | 29,313 | 7,515 | 45,265 |
| Proceeds from sale of assets held for sale, net of costs to sell | 3,637 | - | - | - |
| Purchase of property and equipment | 1,096 | 1,351 | 1,363 | 2,900 |
| Net cash flow used in investing activities | -17,133 | -4,950 | -14,281 | 11,303 |
| Options exercised by executives and directors | - | 0 | 0 | 0 |
| Net shares repurchased for employee taxes | 814 | -1 | 0 | 370 |
| Cash dividends paid to stockholders | 87 | 0 | 0 | 195 |
| Stock repurchases | - | 0 | - | - |
| Net cash flow used in financing activities | -901 | 1 | 0 | -565 |
| Foreign currency impact | - | 4 | 0 | 0 |
| Increase in cash and cash equivalents | -17,774 | -10,223 | -2,168 | 10,766 |
| Cash and cash equivalents - beginning of the period | 89,303 | 99,526 | 90,928 | - |
| Cash and cash equivalents - end of period | 71,529 | 89,303 | 99,526 | - |
MEDIFAST INC (MED)
MEDIFAST INC (MED)